文献速递冠心病血脂与心血管预防

访视间胆固醇变异性与冠状动脉粥样硬化进展及临床结局相关

Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.
PubMed 文献 · Eur Heart J · 2018-01-01

该研究对9项临床试验中4976例冠心病患者进行事后分析,采用系列血管内超声评估斑块进展。结果显示,致动脉粥样硬化脂蛋白的访视间变异性越大,斑块体积百分比进展越显著,且与主要不良心血管事件呈阶梯式相关;但达标脂蛋白水平与斑块进展的关联更强。

要点

  • 致动脉粥样硬化脂蛋白访视间变异性越大,斑块进展风险越高。
  • 脂蛋白变异性最高的四分位组主要不良心血管事件显著增加。
  • 达标脂蛋白水平与斑块进展的关联强于变异性,强调低且稳定的脂蛋白水平。

核心结论

  • 致动脉粥样硬化脂蛋白水平的访视间变异性越大,与冠状动脉斑块进展和临床结局显著相关。
  • 达标致动脉粥样硬化脂蛋白水平与斑块进展的关联似乎更强。
  • 实现低且稳定的致动脉粥样硬化脂蛋白水平有助于促进斑块消退和改善临床结局。

研究设计与样本

  • 对9项临床试验进行患者水平事后分析,共纳入4976例接受多种药物治疗并系列血管内超声检查的冠心病患者。
  • 评估斑块体积百分比进展、临床结局与访视间脂质变异性(LDL-C、HDL-C、非HDL-C、TC/HDL-C、ApoB)的关联。
  • 脂质参数变异性采用3、6、12、18和24个月内的个体内标准差衡量。

主要发现

  • 致动脉粥样硬化脂蛋白变异性与斑块体积百分比进展显著相关:LDL-C OR 1.09(95%CI 1.02–1.17,P=0.01);非HDL-C OR 1.10(95%CI 1.02–1.18,P=0.01);TC/HDL-C OR 1.14(95%CI 1.06–1.24,P=0.001);ApoB OR 1.13(95%CI 1.03–1.24,P=0.01)。
  • 24个月随访时,致动脉粥样硬化脂蛋白变异性四分位组与累积主要不良心血管事件呈显著阶梯关系(除HDL-C外,log-rank P<0.01)。
  • 达标脂蛋白水平与斑块体积百分比进展的关联更强:LDL-C OR 1.27(95%CI 1.17–1.39,P<0.001);非HDL-C OR 1.32(95%CI 1.21–1.45,P<0.001);TC/HDL-C OR 1.31(95%CI 1.19–1.45,P<0.001);ApoB OR 1.20(95%CI 1.07–1.35,P=0.003)。

临床怎么用

  • 在冠心病二级预防中,除关注脂蛋白达标水平外,还应重视访视间脂蛋白水平的稳定性。
  • 对致动脉粥样硬化脂蛋白波动较大的患者,可考虑加强监测和干预以促进斑块消退。

局限性

  • 本研究为事后分析,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Utilizing serial intravascular ultrasonography (IVUS), we aimed to exam the association of intra-individual lipid variability, coronary atheroma progression, and clinical outcomes. METHODS AND RESULTS: We performed a post hoc patient-level analysis of nine clinical trials involving 4976 patients with coronary artery disease who underwent serial coronary IVUS in the setting of a range of medical therapies. We assessed the associations between progression in percent atheroma volume (ΔPAV), clinical outcomes, and visit-to-visit lipid variability including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC)/HDL-C, and apolipoprotein B (ApoB). Variability of lipid parameters was measured using intra-individual standard deviation over 3, 6, 12, 18, and 24 months. Atherogenic lipoprotein variability significantly associated with ΔPAV [odds ratio (95% confidence interval; P-value), LDL-C: 1.09 (1.02, 1.17, P = 0.01); non-HDL-C: 1.10 (1.02, 1.18, P = 0.01); TC/HDL-C: 1.14 (1.06, 1.24, P = 0.001); ApoB: 1.13 (1.03, 1.24, P = 0.01)]. Survival curves revealed significant stepwise relationships between cumulative major adverse cardiovascular events and increasing quartiles of atherogenic lipoprotein variability at 24-months follow-up (log-rank P < 0.01 for all lipoproteins except HDL-C). Stronger associations were noted between achieved lipoprotein levels and ΔPAV [LDL-C: 1.27 (1.17, 1.39; P < 0.001); non-HDL-C: 1.32 (1.21, 1.45; P < 0.001); TC/HDL-C: 1.31 (1.19, 1.45; P < 0.001); ApoB: 1.20 (1.07, 1.35; P = 0.003)]. CONCLUSION: Greater visit-to-visit variability in atherogenic lipoprotein levels significantly associates with coronary atheroma progression and clinical outcomes, although the association between achieved atherogenic lipoproteins and atheroma progression appears stronger. These data highlight the importance of achieving low and consistent atherogenic lipoprotein levels to promote plaque regression and improve clinical outcomes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Clark D, Nicholls SJ, St John J, et al. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. Eur Heart J. 2018. PMID: 29688308. doi:10.1093/eurheartj/ehy209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。